These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 26269694)

  • 1. Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V.
    Fuji T; Fujita S; Kawai Y; Nakamura M; Kimura T; Fukuzawa M; Abe K; Tachibana S
    Thromb J; 2015; 13():27. PubMed ID: 26269694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Edoxaban versus enoxaparin for the prevention of venous thromboembolism after total knee or hip arthroplasty: pooled analysis of coagulation biomarkers and primary efficacy and safety endpoints from two phase 3 trials.
    Kawai Y; Fuji T; Fujita S; Kimura T; Ibusuki K; Abe K; Tachibana S
    Thromb J; 2016; 14():48. PubMed ID: 27980462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial.
    Fuji T; Wang CJ; Fujita S; Kawai Y; Nakamura M; Kimura T; Ibusuki K; Ushida H; Abe K; Tachibana S
    Thromb Res; 2014 Dec; 134(6):1198-204. PubMed ID: 25294589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery.
    Fuji T; Fujita S; Kawai Y; Nakamura M; Kimura T; Kiuchi Y; Abe K; Tachibana S
    Thromb Res; 2014 Jun; 133(6):1016-22. PubMed ID: 24680549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan.
    Fuji T; Wang CJ; Fujita S; Kawai Y; Kimura T; Tachibana S
    J Arthroplasty; 2014 Dec; 29(12):2439-46. PubMed ID: 25047458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis.
    Feng W; Wu K; Liu Z; Kong G; Deng Z; Chen S; Wu Y; Chen M; Liu S; Wang H
    Thromb Res; 2015 Dec; 136(6):1133-44. PubMed ID: 26498222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
    Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
    Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial.
    Weitz JI; Bauersachs R; Becker B; Berkowitz SD; Freitas MCS; Lassen MR; Metzig C; Raskob GE
    JAMA; 2020 Jan; 323(2):130-139. PubMed ID: 31935028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thromboprophylaxis with dabigatran after total hip arthroplasty in Indian patients: A subanalysis of a double-blind, double-dummy, randomized RE-NOVATE II study.
    Malhotra R; Babhulkar S; Sanjib KB; Clemens A; Dadi A; Iyer R; Kamath S; Mody B; Mutha S; Reddy G; Shah V; Shah V; Shetty N; Tapasvi S; Wadhwa M
    Asian J Surg; 2017 Apr; 40(2):145-151. PubMed ID: 27143213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
    Raskob GE; van Es N; Segers A; Angchaisuksiri P; Oh D; Boda Z; Lyons RM; Meijer K; Gudz I; Weitz JI; Zhang G; Lanz H; Mercuri MF; Büller HR;
    Lancet Haematol; 2016 Aug; 3(8):e379-87. PubMed ID: 27476789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspirin versus enoxaparin for the initial prevention of venous thromboembolism following elective arthroplasty of the hip or knee: A systematic review and meta-analysis.
    Farey JE; An VVG; Sidhu V; Karunaratne S; Harris IA
    Orthop Traumatol Surg Res; 2021 Feb; 107(1):102606. PubMed ID: 32631716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin.
    Fuji T; Ochi T; Niwa S; Fujita S
    J Orthop Sci; 2008 Sep; 13(5):442-51. PubMed ID: 18843459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
    Eriksson BI; Dahl OE; Huo MH; Kurth AA; Hantel S; Hermansson K; Schnee JM; Friedman RJ;
    Thromb Haemost; 2011 Apr; 105(4):721-9. PubMed ID: 21225098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy and safety of anticoagulants for prevention of venous thromboembolism after hip and knee arthroplasty.
    Hur M; Park SK; Koo CH; Jung ED; Kang P; Kim WH; Kim JT; Jung CW; Bahk JH
    Acta Orthop; 2017 Dec; 88(6):634-641. PubMed ID: 28787226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    ; Büller HR; Décousus H; Grosso MA; Mercuri M; Middeldorp S; Prins MH; Raskob GE; Schellong SM; Schwocho L; Segers A; Shi M; Verhamme P; Wells P
    N Engl J Med; 2013 Oct; 369(15):1406-15. PubMed ID: 23991658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study.
    Colwell CW; Berkowitz SD; Davidson BL; Lotke PA; Ginsberg JS; Lieberman JR; Neubauer J; McElhattan JL; Peters GR; Francis CW
    J Thromb Haemost; 2003 Oct; 1(10):2119-30. PubMed ID: 14521593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
    Eriksson BI; Borris LC; Friedman RJ; Haas S; Huisman MV; Kakkar AK; Bandel TJ; Beckmann H; Muehlhofer E; Misselwitz F; Geerts W;
    N Engl J Med; 2008 Jun; 358(26):2765-75. PubMed ID: 18579811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2).
    Eriksson BI; Turpie AG; Lassen MR; Prins MH; Agnelli G; Kälebo P; Wetherill G; Wilpshaar JW; Meems L;
    J Thromb Haemost; 2010 Apr; 8(4):714-21. PubMed ID: 20088935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty.
    Fuji T; Fujita S; Tachibana S; Kawai Y
    J Thromb Haemost; 2010 Nov; 8(11):2458-68. PubMed ID: 20723033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
    Lassen MR; Fisher W; Mouret P; Agnelli G; George D; Kakkar A; Mismetti P; Turpie AG;
    J Thromb Haemost; 2012 May; 10(5):822-32. PubMed ID: 22429800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.